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dRecombinant human insulin was encapsulated within alginate microspheres by the emulsification/internal gelation technique with the objective of
reserving protein stability during encapsulation procedure. The influence of process and formulation parameters was evaluated on the morphology
nd encapsulation efficiency of insulin. The in vitro release of insulin from microspheres was studied under simulated gastrointestinal conditions
nd the in vivo activity of protein after processing was assessed by subcutaneous administration of extracted insulin from microspheres to
treptozotocin-induced diabetic rats. Microspheres mean diameter, ranging from 21 to 287m, decreased with the internal phase ratio, emulsifier
oncentration, mixer rotational speed and increased with alginate concentration. Insulin encapsulation efficiency, near 75%, was not affected by
mulsifier concentration, mixer rotational speed and zinc/insulin hexamer molar ratio but decreased either by increasing internal phase ratio and
alcium/alginate mass ratio or by decreasing acid/calcium molar ratio and alginate concentration. A high insulin release, above 75%, was obtained
t pH 1.2 and under simulated intestinal pH a complete dissolution of microspheres occurred. Extracted insulin from microspheres decreased
yperglycemia of diabetic rats proving to be bioactive and showing that encapsulation in alginate microspheres using the emulsification/internal
elation is an appropriate method for protein encapsulation.
2006 Elsevier B.V. All rights reserved.
eywords: Alginate; Bioactivity; Insulin; Internal gelation; Microspheres
. Introduction
Despite the major advances that have occurred, since insulin
ntroduction in 1922, relating to production, purification and
harmaceutical formulation, insulin-replacement therapy is far
rom ideal. The optimal method of insulin delivery must be
afe, should provide insulin to diabetic patients in a way that
ill correct the metabolic abnormalities of diabetes mellitus,
nd must be psychologically and socially acceptable (Brange
nd Langkjaer, 1997). Although oral administration of insulin
s of greatest interest, its low bioavailability has not permit-
ed to achieve an efficient formulation. The entrapment within
∗ Corresponding author. Tel.: +351 239 855085; fax: +351 239 855099.
E-mail address: catarinasilva@ci.uc.pt (C.M. Silva).
microparticulate drug delivery systems, using various kinds
of polymers and techniques has been extensively investigated
(Damge et al., 1988; Morishita et al., 1992; Mathiowitz et al.,
1997; Lowman et al., 1999; Agarwal et al., 2001) to increase the
poor permeability across intestinal epithelia and avoid destruc-
tion by proteolytic intestinal enzymes. However, in the devel-
opment of new protein delivery methods, there are several key
points that have to be considered, namely, the impact of manu-
facturing on the integrity of the protein (Cleland et al., 2001).
During the formation of microspheres, the protein molecules
are often exposed to heat, mechanic stirring, adsorption onto
matrix polymer, exposure to organic solvents and surface ten-
sion, which may result in a different molecular deterioration
of the protein, such as molecular breakdown, denaturation
and aggregation (Li et al., 2000). Thus, a mild encapsula-
tion method avoiding stress conditions should be selected to
378-5173/$ – see front matter © 2006 Elsevier B.V. All rights reserved.
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minimize protein denaturation and the loss of its biological
activity.
Alginate is a non-toxic, biodegradable, natural occurring
polysaccharide obtained from marine brown algae. It is a linear
copolymer composed of 1,4-linked--d-mannuronic acid and
-l-guluronic acid residues that gels in the presence of diva-
lent cations, such as calcium, due to the stacking of guluronic
acid (G) blocks with the formation of “egg-box” calcium linked
junctions (Martinsen et al., 1989). Alginate microspheres have
been used for the encapsulation of a wide variety of biolog-
ically active agents, including proteins (Coppi et al., 2002),
enzymes (Boadi and Neufeld, 2001), antibodies (Albarghouthi
et al., 2000), cells (Klinkenberg et al., 2001) and DNA (Quong
and Neufeld, 1998), due to the relatively mild crosslinking
conditions of preparation. In particular, calcium–alginate micro-
spheres were used to encapsulate insulin by using an extrusion
process (Gray and Dowsett, 1988) and an encapsulation effi-
ciency of 65% was obtained. Insulin was also encapsulated in
chitosan-coated alginate microspheres (Hari et al., 1996) but
the encapsulation efficiency was very low (11%). Strategies to
increase the encapsulation efficiency included the complexation
of insulin with -cyclodextrin (Moses et al., 2000) or the incor-
poration of insulin in liposomes (Ramdas et al., 2000) before the
encapsulation in alginate microspheres.
Microspheres having less than 100m can be produced by
the emulsification/internal gelation technique (Poncelet et al.,
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spheres was approximately 97% (Onal and Zihnioglu, 2002) and
93% (Wang and He, 2002) and these high values may be justified
by the fact that in both studies the pH of the processing medium
was below the isoelectric point of insulin (pI = 5.3), favouring
the electrostatic interaction between the protein and alginate.
In this work, the studied process variables were related to the
emulsification process and included emulsifier concentration,
internal phase ratio and impeller rotational speed. Factors influ-
encing alginate gelling properties, such as calcium/alginate mass
ratio, acid/calcium molar ratio and alginate concentration, were
also evaluated. Insulin was dissolved in an acetate zinc solution
to study the molar ratio between zinc ion and insulin, which may
influence insulin degree of association and solubility. When zinc
or other divalent metal ions are present, the hexameric form of
insulin prevails in neutral and moderately alkaline solutions even
at low protein concentrations (Brange et al., 1987).
Furthermore, the in vitro release profile of insulin in simu-
lated gastrointestinal conditions was studied and insulin stability
was assessed by bioactivity studies to ensure that insulin-loaded
microspheres were able to preserve protein stability during par-
ticle processing and recovery.
2. Materials and methods
2.1. Materials
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a992) by dispersing an alginate solution containing an insoluble
alcium salt into an oil. Gelation is achieved by gentle acidifi-
ation with an oil-soluble acid that causes calcium ion release.
mall-sized alginate microspheres may be an adequate system
or oral insulin administration since they permit a predictable
astrointestinal transit time and an increased surface area for
nteraction with the intestinal epithelium. Alginate bioadhesive
roperties (Chickering et al., 1997) will be favoured by a more
ntimate contact between intestinal mucosa and lower-sized
icrospheres. Insulin was encapsulated in alginate microspheres
repared by an emulsion-based process (Jerry et al., 2001) but
nsulin content was very low (21 IU/g).
During manufacturing, a large number of parameters may
nfluence the characteristics of the microspheres. We previ-
usly investigated the effect of some process and formulation
arameters on the morphology and protein encapsulation effi-
iency of calcium–alginate microspheres prepared by emulsifi-
ation/internal gelation containing hemoglobin, used as a model
rotein (Silva et al., 2005).
Based on these considerations, the present work investigates
he means for the efficient encapsulation of insulin, which poses
ore difficulties in respect to protein retention inside micro-
pheres, especially due to its lower molecular weight (5.8 kDa),
omparatively to hemoglobin (64 kDa). Process and formulation
ariables were optimized in order to obtain microspheres pre-
enting the lowest size and the highest encapsulation efficiency
f insulin.
The encapsulation efficiency of insulin in alginate micro-
pheres was found to increase when the pH of the processing
edium decreased from 6.0 to 4.0 (Moses et al., 2000). In
ther studies, insulin encapsulation efficiency in alginate micro-Sodium alginate (Algogel® 3541) was obtained from
egussa Texturant Systems (Boulogne-Billancourt, France).
his alginate presented a viscosity measured with a rotational
iscometer (Visco Star plus, Fungilab, S.A., Barcelona, Spain)
or a 1% solution at 20 ◦C of 318 mPa. Span® 80 was pur-
hased from Fluka Biochemika (Steinheim, Germany). Ultrafine
alcium carbonate (Setacarb) was supplied by Omya (Orgon,
rance) and paraffin oil was supplied by Vaz Pereira (Lisbon,
ortugal). Insulin was obtained as a regular human insulin of
ecombinant DNA origin (Actrapid® 100 IU/ml) from Novo
ordisk A/S (Bagsvaerd, Denmark). Streptozotocin was pur-
hased from Sigma (Steinheim, Germany). All other chemicals
sed were of analytical reagent grade.
.2. Methods
.2.1. Preparation of microspheres
Microspheres were prepared by emulsification/internal gela-
ion (Poncelet et al., 1992). A basal encapsulation protocol was
sed to prepare microspheres, which consisted in the follow-
ng. A 2% (w/v) sodium alginate solution was prepared by
issolution of the polymer in insulin solution at 0.1% (w/v)
btained by dilution of Actrapid® formulation in water (1:2,
/v). A suspension of CaCO3 at 5% (w/v) was added to the
lginate solution (7.3% Ca/alginate mass ratio, w/w) and, after
omogenization, the mixture was dispersed into paraffin oil
30% internal phase ratio, v/v) containing 1% (v/v) Span® 80
y stirring at 400 rpm through the use of an Ika-Eurostar® mixer
Ika, Staufen, Germany) equipped with a marine impeller. After
5 min emulsification, 20 ml of paraffin oil containing glacial
cetic acid (acid/Ca molar ratio of 3.5) were added to the w/o
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emulsion and stirring continued to permit calcium carbonate
solubilization. Microspheres were recovered from oily phase by
using an acetate buffer at pH 4.5 (USP XXVII) and succes-
sively washed with this buffer until no more oil was detected
by optical microscope observation. Microspheres were then
frozen in an ethanol bath (Benchtop shell freezer, Freezone®
model 79490, Labconco, USA) at −40 ◦C and freeze-dried
(Lyph-lock 6 apparatus, Labconco, USA) at 0 ◦C for, at least,
48 h.
Process and formulation variables were investigated for opti-
mization of microspheres properties by individually changing
the preparation conditions in the described basal protocol with
all other parameters being held constant. The variables tested
included emulsifier concentration (0, 0.5, and 1%), internal
phase ratio (30, 40, and 50%), mixer rotational speed (200, 400,
and 600 rpm), Ca/alginate mass ratio w/w (5.0, 6.0, 7.3, 8.7, 10.0,
and 16.7%), acid/Ca molar ratio (1.5/1, 2/1, and 3.5/1), alginate
concentration (2.0, 2.5, and 3.0%) and insulin dilution media
(zinc acetate at 0, 0.2, 0.4 and 0.6 mM) that permitted to obtain
different Zn/insulin hexamer molar ratios (2.0, 5.5, 9.0 and 13.0,
respectively). The mean yield for the recovery of microspheres
was 70.3 ± 8.6%.
2.2.2. Morphological and particle size analysis
Morphology of hydrated microspheres was monitored by
optical microscopic observation using an optical microscope
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tein and the total insulin recovered from microspheres. Assays
were performed in triplicate.
2.2.4. In vitro release studies
A multiple stirring points plate was used for in vitro release
studies using simulated gastrointestinal conditions without
enzymes and a stirring rate of 100 rpm. Insulin-loaded micro-
spheres (20 mg) were placed in 20 ml of hydrochloric acid buffer
at pH 1.2 (USP XXVII). After 2 h, the microspheres were trans-
ferred by centrifugation to 20 ml of phosphate buffer at pH 6.8
(USP XXVII) and incubated for 2 h. Two milliliter of sample
was taken at appropriate intervals from both media and anal-
ysed by HPLC as described below. Assays were performed in
triplicate.
2.2.5. Insulin analysis
Samples withdrawn from acidic medium were centrifuged
(13,400 rpm/10 min) and the supernatant was used for insulin
analysis. Samples obtained from phosphate buffer were mixed
with NaOH 0.2 M to raise pH above 7.0 followed by addition of
ethanol (50/50, v/v) to precipitate alginate. After mixing, sam-
ples were centrifuged (13,400 rpm/10 min) and the recovered
supernatant was assayed for insulin.
The concentration of insulin was determined by using an
HPLC system (model HP1100 series, Hewlett Packard, Ger-
many) equipped with an autosampler (Agilent 1100 series,
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tlympus BH2-UMA equipped with a Cue-2 image analyser
Olympus, Tokyo, Japan). The shape and surface texture of
icrospheres was examined by scanning electron microscopy
SEM) (JEOL JSM-840®, 10 kV, Tokyo, Japan). The samples
ere mounted on metal stubs, using double sided adhesive
ape, gold coated under vacuum and then examined. Size dis-
ribution of microspheres was determined in washing media
y laser diffractometry (Fraunhofer model) using a Coulter
S130 particle analyser, with a size range from 0.1 to 1000m.
easurements were made in triplicate for each batch. Particle
ize is expressed as volume mean diameter (m) ± standard
eviation (S.D.) values related to the mean. Polydispersity
as determined by the SPAN factor (El-Mahdy et al., 1998)
xpressed as SPAN = [D(v, 90) − D(v, 10)]/D(v, 50), where
(v, 90), D(v, 10) and D(v, 50) are volume size diameters at
0, 10 and 50% of the cumulative volume, respectively. A high
alue of SPAN indicates a wide distribution in size and a high
olydispersity.
.2.3. Encapsulation efficiency
To determine the encapsulation efficiency of insulin, 10 mg
f lyophilized insulin-loaded microspheres were accurately
eighed and incubated in 10 ml of hydrochloric acid buffer at
H 1.2 (USP XXVII), under magnetic stirring (100 rpm/2 h).
icrospheres were then transferred by centrifugation into 10 ml
hosphate buffer at pH 6.8 (USP XXVII) and magnetically
tirred during 1 h, to obtain complete dissolution. Samples were
ithdrawn after acid and phosphate incubation and analysed by
igh performance liquid chromatography (HPLC) as described
elow. The encapsulation efficiency of insulin was calculated
rom the difference between the theoretical initial amount of pro-ermany). A reversed-phase X-Terra C-18 column, 5m,
.6 mm × 250 mm (Waters, USA), with a Purospher® STAR
P-18 precolumn, 5m, 4 mm × 4 mm (Merck, Germany) was
mployed. Mobile phase A consisted of 0.04% trifluoroacetic
cid (TFA) in water and mobile phase B was 0.04% TFA in ace-
onitrile. A linear gradient of 30–40% B over 5 min was used
ith a flow rate of 1.2 ml/min. Injections of 20l were made
ith the autosampler. The UV detector was set at 210 nm and
PLC analysis was carried at 27 ◦C. A retention time of 4.5 min
as obtained.
.2.6. Diabetic animal model
Wistar male rats, weighting between 250 and 350 g, were
asted for 16–19 h prior to inducing diabetes mellitus with free
ccess to water. A solution of streptozotocin (STZ) at 20 mg/ml
n citrate buffer at pH 4.5 was freshly prepared and used within
h. Prior to injection, a drop of blood was collected from the
ail vein to determine baseline blood glucose levels. Each rat
as injected with a single intraperitoneal (i.p.) dose of STZ
olution at 50 mg/kg, 48 h before the study. During the first 24 h,
ats were given 5% glucose to prevent hypoglycemia due to
estruction of pancreatic -cells. Fasted rats presenting a blood
lucose level higher than 250 mg/dl were considered diabetic.
lucose was measured by using a Medisense® Precision Xtra
lycometer (Abbott, Bedford, USA). Animal treatments were
erformed according to the Portuguese law (DL n. 197/96) and
he institutional European guidelines (EEC n. 86/609).
.2.7. Determination of bioactivity of insulin
In order to determine bioactivity of insulin during encapsula-
ion procedure and microspheres recovery, 30 mg of lyophilized
4 C.M. Silva et al. / International Journal of Pharmaceutics 311 (2006) 1–10
microspheres were suspended in PBS (10 ml) at 20 ◦C for 2 h.
After centrifugation (3000 rpm/2 min) the supernatant was fil-
tered through a 0.45m pore size filter and the filtered solution
was assayed for insulin content by HPLC, as described above.
Blank microspheres, prepared without insulin, were treated in
the same conditions and the supernatant used as negative con-
trol. The hypoglycemic effect was compared with that of rats
given Actrapid® (100 IU/ml) dissolved in filtered PBS in order
to obtain the same concentration achieved with insulin micro-
spheres, used as positive control.
A dose of 4 IU/kg was injected subcutaneously into groups
of eight diabetic rats fasted for at least 16 h. Identical volumes
of 1 ml/kg were used for the sample and positive and negative
controls. Blood samples were collected from the tail vein after
30 min and 2 h, corresponding to the onset and peak of action
of regular insulin and assayed for blood glucose levels. After
24 h, glycemia was measured to confirm the hyperglycemic
state.
2.2.8. Statistical analysis
Each value was expressed as the mean ± S.D. Statistical dif-
ferences were analysed by using a one-way analysis of variance
(ANOVA) followed by a Bonferroni post-test. For a value of
P < 0.05 the difference was considered significant.
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Table 2
Effect of formulation variables on size distribution, insulin loading and encap-
sulation efficiency of microspheres
Mean size (m) SPAN
factor
Insulin loading
(%, w/w)
Encapsulation
efficiency (%, w/w)
Ca/alginate ratio (%, w/w)
5.0 61.9 ± 18.5 0.80 3.87 ± 0.20 70.1 ± 3.6
6.0 61.2 ± 15.0 0.67 3.65 ± 0.12 66.2 ± 2.3
7.3a 53.0 ± 12.9 0.66 4.18 ± 0.10 75.8 ± 1.8
8.7 45.6 ± 13.8 0.77 3.90 ± 0.02 70.8 ± 0.3
10.0 55.2 ± 16.2 0.80 3.61 ± 0.02 65.5 ± 0.4
16.7 48.8 ± 11.5 0.64 3.60 ± 0.05 65.3 ± 1.0
Acid/Ca molar ratio
1.5 55.3 ± 15.9 0.79 3.58 ± 0.10 64.9 ± 1.8
2.0 47.3 ± 11.5 0.66 3.96 ± 0.07 71.8 ± 1.3
3.5a 53.0 ± 12.9 0.66 4.18 ± 0.10 75.8 ± 1.8
Alginate concentration (%, w/v)
2.0a 53.0 ± 12.9 0.66 4.18 ± 0.10 75.8 ± 1.8
2.5 97.1 ± 44.3 1.32 3.44 ± 0.07 77.2 ± 1.5
3.0 112.2 ± 79.1 1.77 2.91 ± 0.10 77.9 ± 2.8
Zn/insulin hexamer ratio
2.0a 53.0 ± 12.9 0.66 4.18 ± 0.10 75.8 ± 1.8
5.5 46.4 ± 11.4 0.67 4.13 ± 0.07 75.0 ± 1.3
9.0 46.4 ± 12.9 0.75 4.37 ± 0.07 79.2 ± 1.3
13.0 45.4 ± 12.1 0.72 4.09 ± 0.07 74.2 ± 1.4
Microspheres were prepared by using the standard conditions. Data are shown
as mean ± S.D.
a Standard preparation conditions.
altering the formulation variables caused mean diameter to vary
from 45 to 112m (Table 2).
All the studied process variables had influence on the mean
diameter, especially the emulsifier concentration and the mixer
rotational speed. An increase in the emulsifier concentration
resulted in a decrease in the microspheres mean size from 288
to 53m. For microspheres prepared with 0.5% and without
emulsifier, standard deviations of the mean diameter were 35
and 59%, respectively, while in the case of microspheres pre-
pared with 1% of emulsifier a lower standard deviation of 24%
was obtained. Microspheres polydispersity obtained from the
calculation of SPAN factor agreed with relative standard devia-
tion results since values decreased from 1.74 to 0.66 when the
emulsifier concentration was increased. Increasing the mixer
rotational speed from 200 to 600 rpm resulted in a nine-fold
decrease in microspheres mean size (Fig. 1). The SPAN fac-
tor for microspheres prepared at 400 rpm was 0.66, but when
the mixer speed was changed, either to 200 or 600 rpm, higher
values of 2.19 and 0.78 were, respectively, achieved. On the
other hand, an increase on the internal/external phase ratio
during the emulsification step from 30 to 50%, while keep-
ing total liquid volume constant, led to a decrease in micro-
spheres mean size from 53 to 27m. Nevertheless polydisper-
sity was not altered since the SPAN factor values were very
similar.
Within formulation parameters only alginate concentration
a
f. Results
.1. Morphological and size characteristics
Mean diameter values of alginate microspheres prepared
sing different process and formulation variables are presented
n Tables 1 and 2, as well the standard deviation values related to
he mean and the SPAN factor, which elucidate about the peak
idth. Microspheres mean diameter ranged from 21 to 288m
hile changing process variables (Table 1). On the other hand,
able 1
ffect of process variables on size distribution, insulin loading and encapsulation
fficiency of microspheres
Mean size (m) SPAN
factor
Insulin loading
(%, w/w)
Encapsulation
efficiency (%, w/w)
mulsifier concentration (%)
0 287.5 ± 169.7 1.74 4.17 ± 0.05 75.6 ± 0.8
0.5 74.2 ± 26.2 0.96 4.09 ± 0.04 74.2 ± 0.7
1.0a 53.0 ± 12.9 0.66 4.18 ± 0.10 75.8 ± 1.8
nternal phase ratio (%)
30a 53.0 ± 12.9 0.66 4.18 ± 0.10 75.8 ± 1.8
40 41.7 ± 26.6 0.69 3.89 ± 0.06 70.5 ± 1.1
50 26.6 ± 6.9 0.70 3.63 ± 0.12 65.8 ± 2.2
mpeller rotational speed (rpm)
200 188.5 ± 149.0 2.19 3.93 ± 0.08 71.3 ± 1.5
400a 53.0 ± 12.9 0.66 4.18 ± 0.10 75.8 ± 1.8
600 21.2 ± 6.5 0.78 4.06 ± 0.04 73.6 ± 0.6
icrospheres were prepared by using the standard conditions. Data are shown
s mean ± S.D.
a Standard preparation conditions.ffected mean size. When alginate concentration was increased
rom 2 to 3% (w/v) the particle diameter increased from 53
C.M. Silva et al. / International Journal of Pharmaceutics 311 (2006) 1–10 5
Fig. 1. Volume size distribution of microspheres formed at different mixer rota-
tional speed: 200 rpm (), 400 rpm () and 600 rpm (). Microspheres were
prepared by using the standard conditions.
to 112m and this increase in size was accompanied with an
increase in SPAN factor from 0.66 to 1.77. Concentrations of
alginate above 3% were assayed however microspheres manu-
facturing became difficult due to the increase in the viscosity of
alginate solution.
Ca/alginate mass ratio and acid/Ca molar ratio, parame-
ters influencing the gelation characteristics of the polymer, did
not appear to influence mean size of microspheres. However,
decreasing Ca/alginate ratio (w/w) caused a slight increase on
mean size.
During the aqueous phase preparation, before the emulsifi-
cation step of microspheres preparation, insulin was diluted in
water or zinc acetate solution at different concentrations, in order
to obtain Zn/insulin hexamer ratios ranging from 2.0 to 13.0 but
mean size and size distribution were not considerably altered by
this parameter.
Regardless of size variations occurring by changing process
and formulation variables, microspheres were always disperse
and spherical as illustrated in Fig. 2a and no aggregation of
microspheres was observed. Tubular and star-like structures
Fig. 3. Morphology and size of insulin-loaded alginate microspheres accord-
ing to SEM micrograph (magnification 1000×) prepared by using the standard
conditions.
were visible in the microspheres and attributed to the presence
of insulin, since they were not present in blank microspheres
prepared without insulin (Fig. 2b). SEM micrograph (Fig. 3)
confirmed this observation showing a smooth surface on which
the mentioned tubules were present.
3.2. Encapsulation efficiency
The analysis of insulin content and encapsulation efficiency
within microspheres prepared using different process and for-
mulation parameters are reported in Tables 1 and 2, respectively.
Emulsifier concentration and mixer rotational speed did not
affect encapsulation efficiency of insulin inside microspheres
(P > 0.05), while increasing internal phase volume from 30 to
50% led to a significant decrease of 10% (P < 0.001) in encapsu-
lation efficiency. Insulin loading varied proportionally to encap-
sulation efficiency since the drug/polymer ratio was maintained
constant.
e micrFig. 2. Optical microphotograph of insulin-loaded (a) and blank (b) alginat ospheres (magnification 200×) prepared by using the standard conditions.
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In respect to formulation parameters, values of encapsulation
efficiency varied from 65 to 79% and were especially affected
by parameters influencing alginate gelation, such as Ca/alginate
mass ratio and acid/Ca molar ratio. No systematic effect of
Ca/alginate mass ratio was observed, but higher efficiency was
obtained with a Ca/alginate ratio of 7.3% and then increasing
the proportion of Ca2+ resulted in significantly lower values
(P < 0.001). In the case of acid/Ca molar ratio, the encapsulation
efficiency decreased from 76 to 65% (P < 0.05) by decreasing
the proportion of acid from 3.5 to 1.5.
Raising alginate concentration from 2 to 3% did not cause sig-
nificant changes on insulin encapsulation efficiency (P > 0.05).
On the contrary, a decrease in insulin loading from 4.2 to 2.9%
was obtained, due to a higher polymer/drug ratio.
Increasing Zn/hexamer ratio from 2.0 to 5.5 or 13.0 did not
change the protein encapsulation; however a Zn/hexamer ratio
of 9.0 increased insulin encapsulation in microspheres.
3.3. Insulin release
Under simulated gastric pH, insulin-loaded alginate micro-
spheres presented a high protein release, near 80% (Fig. 4),
independently of process or formulation variables used, with
exception to alginate concentration. A fast and almost total
insulin release, reaching 75%, occurred within 5 min followed
b
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Fig. 5. HPLC chromatograms of (a) insulin released from alginate microspheres
after incubation in PBS and (b) insulin standard.
3.4. Bioactivity of insulin
The chromatogram of insulin released from microspheres
after incubation in PBS had identical retention time to the
insulin standard and no transformation products were detected
(Fig. 5), such as the A21 desamido-insulin, which suggested the
maintenance of insulin stability after microsphere manufacture,
recovery and lyophilization (Jiang et al., 2003). Nevertheless,
the bioactivity was evaluated in vivo by subcutaneously inject-
ing the insulin released from microspheres after incubation in
PBS. The serum glucose concentration of the STZ-induced dia-
betic rats decreased to a normal level (<120 mg/dl) within 30 min
after administration of the solution (Fig. 6). A further decrease
was obtained 2 h after administration reaching approximately
10% of the initial blood glucose levels. This behaviour was sim-
ilar for the rats injected with Actrapid® as a positive control. The
differences between extracted insulin and Actrapid® were not
significant for both sampling withdrawal times (P = 0.263 and
F
o
e
my a slow release which led to a total cumulative release of 80%.
fter changing to intestinal pH, a fast and complete dissolution
f microspheres occurred, permitting an immediate total insulin
elease. It is important to note that increasing alginate concen-
ration caused a slightly higher retention of protein at pH 1.2.
nsulin release in acidic medium decreased from 81.9 to 77.8
nd 73.8% when alginate concentration increased from 2 to 2.5
nd 3% (data not shown), however a complete dissolution was
lso observed after transferring microspheres to intestinal pH.
evertheless, due to the higher viscosity of alginate solution,
anufacture becomes difficult with concentrations higher than
.5%.
ig. 4. In vitro release profile of insulin from microspheres prepared following
he standard conditions and incubated in simulated gastric fluid for 2 h and then
n simulated intestinal fluid. The results are the mean of three experiments ± S.D.ig. 6. Effect of insulin injected subcutaneously to STZ-induced diabetic rats
n blood glucose levels: () control, () Actrapid® formulation and () insulin
xtracted from alginate microspheres. The results are the mean of eight experi-
ents ± S.D.
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0.457 for 30 min and 2 h, respectively). The negative control
group, which was given the solution obtained after incubation
of blank microspheres in PBS, exhibited hyperglycemia.
4. Discussion
4.1. Formulation optimization
The emulsification/internal gelation method, used in this
study, prevented the aggregation of microspheres even when no
emulsifier was added to the water/oil emulsion. The aggregation
phenomenon was reported for alginate microspheres obtained
by emulsification/external gelation (Wan et al., 1993) due to the
addition of calcium chloride to the water/oil emulsion, which
may induce the disruption of the emulsion system equilibrium
(Chan et al., 2002). In the internal gelation method only a small
volume of oil-soluble acid previously dispersed in paraffin oil
is added, which should not affect emulsion stability. Besides,
in our study, mineral oil was used as lipophilic phase instead
of iso-octane that presents lower viscosity. When oil viscosity
increases, microspheres size decreases which decreases surface
tension and increases emulsion stability. We do believe that
one of these factors or the combination of both may justify the
absence of aggregation, using the emulsification/internal gela-
tion method.
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Accordingly, to Eq. (1), diameter distribution decreases by
increasing emulsifier concentration, which decreases the inter-
facial tension between the alginate droplets and the oil in the
continuous phase. The surfactant is expected to promote the
stability of the w/o emulsion and, in fact, size was reduced in
the presence of Span® 80. The encapsulation efficiency was
not affected by this parameter although it could be expected
that factors favouring the increase of mean size could increase
encapsulation efficiency due to a reduced surface area. Based in
these results, the highest concentration of emulsifier (1%) that
led to the lowest size was chosen.
The effect of higher stirring speed on microsphere mean
diameter, contributing to a higher heterogeneity of the batch
may be caused by the distribution of turbulent forces through-
out the emulsion (Lim et al., 1997). Since, shear stress is higher
at the tip of the propeller than at the centre, a faster stirring speed
increased this difference, thereby providing a less uniform dis-
tribution of energy and giving rise to microspheres of a wider
size distribution. Thus, an impeller rotational speed of 400 rpm
was chosen to allow the achievement of small microspheres with
a narrow size distribution. Moreover, protein drugs are suscepti-
ble to denaturation when they are submitted to high shear forces
(Shively, 1997).
Increasing the internal phase ratio from 30 to 50% led to a
decrease on microspheres mean size, which disagrees with Eq.
(1) and other studies (Tin et al., 1997; Li et al., 1999; Moslemy
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mIn this study, size distribution of microspheres presented uni-
odal distribution with no secondary peaks, which have been
eported by using the same method (Poncelet et al., 1995; Tin
t al., 1997). In order to obtain unimodal distribution of micro-
pheres, which allows a better control of drug kinetics, some
trategies like the membrane emulsification/internal gelation
ethod (Liu et al., 2003) were developed. However, using the
ethod presented in this study, an identical mean diameter and
PAN factor were obtained.
The size distribution of the recovered microspheres obtained
y emulsification/internal gelation is correlated with the size
istribution of the emulsion droplets. The average size of
roplets is determined by various parameters such as appara-
us design, viscosity of the two immiscible phases and speed
f mixing. A qualitative equation (Eq. (1)) has been proposed
s guide for controlling the size of microspheres (Arshady,
990):
∝ K DVRνdγ
DSNνmCs
(1)
here d is the average droplet (particle) size, K symbolizes
arameters such as apparatus design, type of stirrer, self sta-
ilization, DV the diameter of the vessel, DS the diameter of the
tirrer, R the volume ratio of the droplet phase to suspension
edium, N the stirring speed, νd the viscosity of the droplet
hase, νm the viscosity of the suspension medium, γ the sur-
ace tension between the two immiscible phases and Cs is the
tabilizer concentration. In this study, parameters related to the
essel and stirrer characteristics were made constant. Also, the
iscosity of suspension medium was not altered since the same
araffin oil was used in all formulations.t al., 2002) where it was verified that a higher proportion of dis-
ersed phase produce an overall increase in mean size, justified
y an increase in the frequency of collisions during emulsifica-
ion, resulting in the formation of aggregates. Previously it was
erified, during hemoglobin encapsulation, that increasing inter-
al phase ratio resulted in a slight decrease in the mean size (Silva
t al., 2005) and, in this study, using the same methodology,
hese differences were further evidenced. The decrease in mean
ize was associated with a decrease in insulin encapsulation,
ot observed when emulsifier concentration and stirring speed
ere changed. One possible explanation is that when aqueous/oil
hase proportion changes, the oil barrier against protein loss may
ecome less significant for a higher internal phase ratio. Thus,
30% ratio was chosen for the standard formulation, because
he effect of internal/external phase ratio on the encapsulation
fficiency was considered more important comparatively to the
ean size of microspheres.
It is difficult to establish a frontier between process and
ormulation variables, for example, alginate concentration is a
ormulation variable that also may be considered as a process
ariable, since increasing alginate concentration increases the
iscosity of the internal phase during the emulsification step
nd a higher energy level is necessary to disperse high viscosity
olutions. Contrary to the expected effect of alginate concen-
ration on microspheres mean size and peak width, related to a
igher resistance to the dispersive forces in the emulsification
tep and reduction on the efficiency of stirring, no important
ffect of this parameter on insulin encapsulation was found.
Parameters directly related to the gelation characteristics
f the polymer, such as Ca/alginate mass ratio and acid/Ca
olar ratio, did not present great influence on mean size of
8 C.M. Silva et al. / International Journal of Pharmaceutics 311 (2006) 1–10
microspheres. The slight decrease in particle size observed
when higher Ca/alginate mass ratio was used may be due to
a more extensive gel shrinkage because more calcium is avail-
able for gelation (Ostberg et al., 1993). It is well established that
calcium–alginate gels shrink during gel formation due to water
loss (Martinsen et al., 1989).
In the case of increased acid/Ca molar ratio a similar effect
could be expected since the acid is responsible for calcium
release. Considering the reaction between acetic acid and cal-
cium carbonate, each mole of CaCO3 reacts with 2 mol of
CH3COOH. When an acid/Ca molar ratio of 1.5 was used the
amount of acetic acid was insufficient to dissolve all the amount
of CaCO3 added to alginate solution, since it was below the
stoichiometric proportion. However, it is thought that, as micro-
spheres are recovered in acetate buffer at pH 4.5, the undissolved
calcium carbonate that may exist inside the microspheres is
dissolved and the effect of acetic acid/Ca molar ratio is imper-
ceptible.
Ca/alginate molar ratio influenced significantly encapsula-
tion efficiency of insulin. It was observed (Poncelet, 2001),
that a Ca/alginate monomer ratio of 1/4 (corresponding to a
5% Ca/alginate mass ratio w/w) was sufficient to ensure strong
microsphere formation however, in this study, we found that a
higher encapsulation efficiency of insulin was obtained with a
Ca/alginate ratio of 7.3% and that calcium ions should not be
in a high excess, in relation to alginate, which permits to con-
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lation efficiency could increase. In solutions of insulin at pH 7.0
with two zinc ions per six monomers of insulin, the hexameric
form comprises 75% or more of total insulin at a concentra-
tion above 100g/ml. The Zn–insulin complexes are soluble
when the Zn/insulin (hexameric) ratio is below 4, but at higher
concentrations of zinc the solubility decreases and when a ratio
of 6 is reached complete precipitation of insulin is observed
(Brange et al., 1987). Actrapid® was diluted in zinc acetate
(ZnAc) at different concentrations to change Zn/hexamer molar
ratio and possibly decrease insulin solubility, so that encapsu-
lation efficiency could increase. This hypothesis was verified
when Zn/hexamer ratio was increased to 9.0 but the decrease
on insulin encapsulation observed for a 13.0 ratio did not con-
firm it. Therefore a ratio of 9.0 was chosen for the optimal
formulation.
The influence of zinc ions on insulin encapsulation efficiency
in alginate microspheres has been previously studied (Gray and
Dowsett, 1988). It was found that when zinc ions are present
in the processing medium, insulin is substantially retained. The
concentrations of zinc chloride ranged from 0.08 to 0.26 M, val-
ues that were substantially higher than those used in this study.
The zinc ions, at these concentrations, could effectively interact
with alginate reducing the pore size of alginate gel, but could also
bind to insulin and form bridges between the protein molecules
and the alginate matrix.
Microspheres produced by emulsification/internal gelation
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elude that alginate degree of gelation was fundamental for the
etention of protein inside microspheres. An increase in cal-
ium concentration was shown to reduce drug encapsulation
fficiency explained by higher degree of gel shrinkage in more
oncentrated calcium chloride solution (Ostberg et al., 1993),
owever in our study the decrease in insulin encapsulation was
ot accompanied with a proportional decrease in size.
The increase of encapsulation efficiency with increasing
cid/Ca molar ratio is explained by an increased availability of
alcium permitting a higher extent of alginate gelation (Amsden
nd Turner, 1999) that led to stronger microspheres, providing
greater resistance to solute transport (Ostberg et al., 1994).
ased on this results a ratio of 3.5 was selected for the optimal
ormulation.
Sodium alginate was dissolved in zinc acetate solution to
tudy the influence of zinc ion on insulin encapsulation effi-
iency, however the polymer is able to complex with zinc,
lthough the association is weaker than with calcium (Aslani
nd Kennedy, 1996). This interaction between alginate and zinc
ould result in a pre-gelation of alginate solution before emul-
ification with an increase in its viscosity and a, subsequently,
ncrease in internal phase droplets mean size. Nevertheless, the
roperties of the alginate solution were not significantly altered
efore the emulsification step probably due to the low Zn con-
entrations employed.
Actrapid formulation is a stable neutral solution containing
pproximately two Zn atoms per insulin hexamer. Using water
o dilute the Actrapid formulation (2:1, v/v) the Zn/hexamer
olar ratio of 2.0 is maintained. Alternatively, Actrapid was
iluted in zinc acetate solution at different concentrations to
hange that ratio and decrease insulin solubility, so that encapsu-sing the chosen values for the different process and formulation
arameters showed an unimodal size distribution with a mean
iameter of 53m and an encapsulation efficiency of insulin
ear 79%. The insulin content of 4.4% (w/w), corresponding to
pproximately 1.3 IU/mg of microspheres, is much higher than
hose obtained by the encapsulation of the same protein either
n chitosan-coated alginate microspheres (Moses et al., 2000)
r liposomes further encapsulated in alginate-chitosan micro-
pheres (Ramdas et al., 2000), 11.0 and 21.5 IU/g of alginate,
espectively.
.2. Insulin release
The effect of pH on Ca–alginate hydrogels network structure
as been neglected. Microspheres incubation, at pH 1.2, causes
alcium ions to be displaced from the polymer network and
he calcium–alginate gel is converted to the unionized form of
lginic acid. After this acid treatment, even if calcium ions do
ot contribute anymore to the stabilization of the microspheres,
he microspheres maintain their macroscopic structure without
ny visible changes in the morphology (Fundueanu et al., 1999;
hou et al., 2001), explained by the formation of hydrogen bonds
hich give a stable structure (Doume`che et al., 2004). This may
ead to dissociation of ionic linkages and reduction in the gel
trength that may favour drug release by diffusion (Ostberg et
l., 1994).
The observed burst release of insulin may be related to the
eak retention of alginate structure. Besides, protein molecules
ispersing close to the microspheres surface diffuse out during
he initial incubation time. In addition, insulin monomers
xhibit hydrophobic regions at the surface of the molecule,
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which could favour interaction with the external oily phase
during emulsification and the localization of insulin at the
surface of microspheres after recovery. As the pH was changed
to 6.8, the alginic acid was converted to a soluble salt of sodium
alginate and the matrix disintegrated, completely releasing the
insulin that was left in microspheres.
Insulin release in acidic media is not compatible with the
susceptibility of the protein to enzymatic attack. For this reason,
the formulation needs to be improved and studies are already on
going concerning the inclusion of other polymers in the alginate
matrix to prevent insulin release at acidic pH.
4.3. Bioactivity
In the emulsification/internal gelation method there is no heat
and the mechanical stress is limited since a stirring speed of only
400 rpm was selected. However, the presence of an air–water or
a water–oil interface, formed during emulsification, may lead
to aggregation and fibril formation of an aqueous solution of
insulin (Sluzky et al., 1991). The protein must maintain intact
its three-dimensional structure and chemical integrity during the
encapsulation process to allow the delivery of the native pro-
tein upon administration (Cleland, 1997). When emulsions are
prepared, the total interfacial area increases as the droplet size
decreases but it was observed that the exposure to the oil–water
interface combined with the mechanical stress of manufacture is
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The size of microspheres was mainly determined by process
parameters such as emulsifier concentration and stirring speed.
Ca/alginate mass ratio and acid/Ca molar ratio significantly
influenced insulin encapsulation. Calcium ions should not be
insufficient in relation to alginate nor be in a high excess,
and the amount of acid should be enough to solubilize cal-
cium carbonate, which permits to conclude that alginate degree
of gelation is fundamental for the retention of protein inside
microspheres.
Encapsulated insulin produced the same bioavailability in
diabetic rats as short-acting insulin formulation showing that
insulin integrity was maintained during microspheres manu-
facturing and recovery. However, at gastric pH, a high protein
release was obtained and further studies should be conducted to
improve this result.
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